[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fdnMIzi_m03zuISoK9o44loIG4ZnEFtT1fZSGUCbbChw":8,"$fx24XtYezO3-c6pmOm6inGE81nyQTZrLH9fvnHLT_CZI":55,"$ffTjgW0oOa7r9GLsGm6JyimKhga8aamh6rT8yIyw_zsg":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},50560,868979,[],"https://cdn.haohuanjiao.com/learnMaterial/ystApp//lrxIhHzEkMVU1s7RJgznM1HzODTgwIJC.png","陆德珉","浙江大学医学院附属第二医院","肿瘤科","主治医师",24,0,"乳腺癌肺转移用药安全指南——关键用药细节全解析","","https://ystcdn.venuertc.com/venue/AI/fb6da58b-fcb4-41f2-b8ff-ea059f951281.jpg","\u003Cdiv class=\"custom-drug-guide-wrapper\">\n  \u003Ch2 id=\"material_title\" class=\"custom-main-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">乳腺癌肺转移用药安全指南——关键用药细节全解析\u003C/h2>\n  \n  \u003Cdiv class=\"custom-intro-section\">\n    💊 \u003Cspan class=\"custom-intro-text\">随着靶向药物、化疗药物和免疫疗法的不断进步，治疗乳腺癌肺部转移时可选择的药品种类越来越多。比如本指南案例中就使用到了伊尼妥单抗（trastuzumab deruxtecan）和艾立布林（eribulin），它们分别属于抗HER2靶向和微管抑制类药物。每类药品在使用时都隐藏着一些容易被忽略的细节。本篇文章专门整理了正使用或者即将使用此类药物时，\u003Cstrong>必须牢记的七大要点\u003C/strong>，帮您安全用药，规避风险。\u003C/span>\n  \u003C/div>\n  \n  \u003C!-- 01 药品类型和作用机制 -->\n  \u003Cdiv class=\"custom-section\">\n    \u003Cdiv class=\"custom-section-bg\">🔬\u003C/div>\n    \u003Ch2 class=\"custom-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">01 药品类型与作用机制\u003C/h2>\n    \u003Cul class=\"custom-clean-list\">\n      \u003Cli>\u003Cstrong>伊尼妥单抗（Trastuzumab deruxtecan）\u003C/strong>：抗HER2靶向药。通过识别并结合HER2蛋白，将细胞毒素直接输送到肿瘤细胞，诱导凋亡。\u003C/li>\n      \u003Cli>\u003Cstrong>艾立布林（Eribulin）\u003C/strong>：微管抑制剂。它阻断细胞分裂过程，抑制肿瘤细胞的增殖。\u003C/li>\n      \u003Cli>不同类型药物靶点不同，注意配合专业医生，严格按照方案选药组合。\u003C/li>\n      \u003Cli>药理机制只需了解大致原理，无需自行调整治疗。\u003C/li>\n    \u003C/ul>\n  \u003C/div>\n  \n  \u003C!-- 02 剂型选择与使用技巧 -->\n  \u003Cdiv class=\"custom-section\">\n    \u003Cdiv class=\"custom-section-bg\">💉\u003C/div>\n    \u003Ch2 class=\"custom-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">02 剂型与使用技巧\u003C/h2>\n    \u003Cul class=\"custom-clean-list\">\n      \u003Cli>\u003Cstrong>剂型\u003C/strong>：\n        \u003Cul>\n          \u003Cli>伊尼妥单抗通常为注射液（静脉输注），由专业医务人员操作。\u003C/li>\n          \u003Cli>艾立布林同样以注射液的形式存在，只能静脉注射。\u003C/li>\n        \u003C/ul>\n      \u003C/li>\n      \u003Cli>正确做法：自行注射风险极高，请全部交由医疗人员完成。\u003C/li>\n      \u003Cli>服药期间需配合体重等生理参数，由医师每次精确计算剂量。\u003C/li>\n    \u003C/ul>\n  \u003C/div>\n  \n  \u003C!-- 03 用药时间和具体用法 -->\n  \u003Cdiv class=\"custom-section\">\n    \u003Cdiv class=\"custom-section-bg\">⏰\u003C/div>\n    \u003Ch2 class=\"custom-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">03 用药频率与具体流程\u003C/h2>\n    \u003Cul class=\"custom-clean-list\">\n      \u003Cli>\u003Cstrong>伊尼妥单抗：\u003C/strong>通常每3周一次，每次静脉滴注，首次给药时间较长以后根据耐受情况缩短。\u003C/li>\n      \u003Cli>\u003Cstrong>艾立布林：\u003C/strong>推荐方案为每三周一个周期，第1、8天静脉注射。\u003Cbr>\n        \u003Cspan class=\"custom-tip\">正确做法：严格记住自己的输液时间；不可擅自更改。\u003C/span>\n      \u003C/li>\n      \u003Cli>漏服处理：应补回当次用药，但请由医师判断如何安排，切勿自作主张。\u003C/li>\n    \u003C/ul>\n  \u003C/div>\n  \n  \u003C!-- 04 药物相互作用须知 -->\n  \u003Cdiv class=\"custom-section\">\n    \u003Cdiv class=\"custom-section-bg\">⚠️\u003C/div>\n    \u003Ch2 class=\"custom-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">04 常见药物相互作用\u003C/h2>\n    \u003Cul class=\"custom-clean-list\">\n      \u003Cli>\u003Cstrong>伊尼妥单抗：\u003C/strong>\n        \u003Cul>\n          \u003Cli>和某些免疫调节药、抗炎药可能增加心脏毒性风险。\u003C/li>\n          \u003Cli>避免与已知QT间期延长的药物合用，防止心律失常。\u003C/li>\n        \u003C/ul>\n      \u003C/li>\n      \u003Cli>\u003Cstrong>艾立布林：\u003C/strong>\n        \u003Cul>\n          \u003Cli>与肝脏酶CYP3A4抑制剂（如抗真菌药、某些抗生素）合用时，药物浓度会上升，需密切监测。\u003C/li>\n          \u003Cli>部分升压药、抗癫痫药与该药物有相互作用。\u003C/li>\n        \u003C/ul>\n      \u003C/li>\n      \u003Cli>正确做法：任何新药或保健品加入时务必提前征询医生。\u003C/li>\n    \u003C/ul>\n  \u003C/div>\n  \n  \u003C!-- 05 特殊人群用药调整 -->\n  \u003Cdiv class=\"custom-section\">\n    \u003Cdiv class=\"custom-section-bg\">👵\u003C/div>\n    \u003Ch2 class=\"custom-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">05 特殊人群用药细节\u003C/h2>\n    \u003Cul class=\"custom-clean-list\">\n      \u003Cli>\u003Cstrong>老年人：\u003C/strong>肝肾功能下降时，药物代谢速度减慢。需根据实际情况减少剂量或延长间隔。\u003C/li>\n      \u003Cli>\u003Cstrong>肝肾功能异常：\u003C/strong>重度功能受损须慎用或停用，决不可自行决定。\u003C/li>\n      \u003Cli>\u003Cstrong>孕妇、哺乳期妇女：\u003C/strong>说明书原则上禁用，因有可能对胎儿或婴儿产生毒性。\u003C/li>\n      \u003Cli>\u003Cstrong>儿童：\u003C/strong>本类药物未明确证实安全性，通常不推荐。\u003C/li>\n      \u003Cli>正确做法：有特殊群体用药需求时请详细告知医务人员所有健康状况。\u003C/li>\n    \u003C/ul>\n  \u003C/div>\n  \n  \u003C!-- 06 常见不良反应及处理 -->\n  \u003Cdiv class=\"custom-section\">\n    \u003Cdiv class=\"custom-section-bg\">❗\u003C/div>\n    \u003Ch2 class=\"custom-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">06 常见不良反应与自我监测\u003C/h2>\n    \u003Cul class=\"custom-clean-list\">\n      \u003Cli>\u003Cstrong>伊尼妥单抗：\u003C/strong>\n        \u003Cul>\n          \u003Cli>过敏反应（如皮疹、气短、低血压），部分患者输液期间会出现发热寒战。\u003C/li>\n          \u003Cli>心脏功能下降、间质性肺病、消化道反应等。\u003C/li>\n        \u003C/ul>\n      \u003C/li>\n      \u003Cli>\u003Cstrong>艾立布林：\u003C/strong>\n        \u003Cul>\n          \u003Cli>神经毒性（麻木、刺痛）、白细胞减少、贫血、脱发等较为常见。\u003C/li>\n          \u003Cli>可出现胃肠反应，如恶心、食欲减退。\u003C/li>\n        \u003C/ul>\n      \u003C/li>\n      \u003Cli>正确做法：\n        \u003Cul>\n          \u003Cli>服药期间时常留意体温、呼吸、心跳是否异常。\u003C/li>\n          \u003Cli>每次化疗前后按医师要求检验白细胞数/心电图。\u003C/li>\n          \u003Cli>一旦发现严重皮疹、呼吸困难或极度乏力等异常，务必及时就医。\u003C/li>\n        \u003C/ul>\n      \u003C/li>\n      \u003Cli>\u003Cspan class=\"custom-data-highlight\">数据显示：\u003C/span>伊尼妥单抗不良反应发生率约在80%以上，绝大多数为可逆、可管理（Cortés et al., 2022）。\u003C/li>\n    \u003C/ul>\n  \u003C/div>\n  \n  \u003C!-- 07 储存条件与稳定性要求 -->\n  \u003Cdiv class=\"custom-section\">\n    \u003Cdiv class=\"custom-section-bg\">🌡️\u003C/div>\n    \u003Ch2 class=\"custom-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">07 储存条件与稳定性要求\u003C/h2>\n    \u003Cul class=\"custom-clean-list\">\n      \u003Cli>两类药品均为注射液，全部存放于\u003Cstrong>医院专业药房\u003C/strong>。\u003C/li>\n      \u003Cli>家用储存几乎无操作空间。如需临时保存（如外带小剂量），应放置2℃~8℃冷藏，避光保存，不可冷冻。\u003C/li>\n      \u003Cli>药物一旦过期、变色或出现浑浊，应立即丢弃。\u003C/li>\n    \u003C/ul>\n  \u003C/div>\n  \n  \u003C!-- 08 临床用药案例提示（不重复，重点用药细节） -->\n  \u003Cdiv class=\"custom-section\">\n    \u003Cdiv class=\"custom-section-bg\">📝\u003C/div>\n    \u003Ch2 class=\"custom-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">08 临床用药案例经验\u003C/h2>\n    \u003Cul class=\"custom-clean-list\">\n      \u003Cli>一位45岁女性在肿瘤科接受伊尼妥单抗联合艾立布林静脉注射，治疗过程中因曾出现骨髓抑制，配合药物剂量下调和血常规随访，未再出现严重不良反应。\u003C/li>\n      \u003Cli>有患者间隔期用药时因未及早复查血象，导致粒细胞异常减少，后续增加检验频次后问题解决。\u003C/li>\n      \u003Cli>现场应用时所有调配及静脉注射均由专业护士完成，患者本人未操作任何用药流程，确保了用药安全。\u003C/li>\n    \u003C/ul>\n  \u003C/div>\n  \n  \u003C!-- 09 药品使用过程中的数据与结论 -->\n  \u003Cdiv class=\"custom-section\">\n    \u003Cdiv class=\"custom-section-bg\">📊\u003C/div>\n    \u003Ch2 class=\"custom-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">09 用药疗效与安全性数据 \u003C/h2>\n    \u003Cul class=\"custom-clean-list\">\n      \u003Cli>伊尼妥单抗的有效率可达60%以上，对HER2过表达患者尤为明显（Modi et al., 2020）。\u003C/li>\n      \u003Cli>艾立布林在控制病情方面显示出延长中位生存期的优势，不良反应多为轻中度，可控制（Kaufman et al., 2014）。\u003C/li>\n      \u003Cli>联合使用时风险叠加，因此监测血象和心肺功能必不可少。\u003C/li>\n    \u003C/ul>\n  \u003C/div>\n  \n  \u003C!-- 10 重点总结与安全提醒 -->\n  \u003Cdiv class=\"custom-section\">\n    \u003Cdiv class=\"custom-section-bg\">🚩\u003C/div>\n    \u003Ch2 class=\"custom-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">10 核心用药建议与温故知新\u003C/h2>\n    \u003Cul class=\"custom-clean-list\">\n      \u003Cli>靶向及化疗药物用法复杂，\u003Cstrong>绝不可自行更改剂量和使用频率\u003C/strong>。\u003C/li>\n      \u003Cli>所有针剂用药全部交由医疗机构执行。发现严重不适或异常反应，\u003Cstrong>切勿拖延，应尽快就医\u003C/strong>。\u003C/li>\n      \u003Cli>特殊人群用药，事先详报健康状况，严防药物意外。\u003C/li>\n      \u003Cli>密切关注用药期间的血液和器官功能指标，每次用药前后配合常规检查。\u003C/li>\n      \u003Cli>药品养护和储存要点牢记在心，如需携带请咨询药师。\u003C/li>\n      \u003Cli>用药期间不随意新增或停用其他药物，防范药物相互作用。\u003C/li>\n    \u003C/ul>\n    \u003Cp class=\"custom-summary\">\u003Cspan class=\"custom-summary-emoji\">⭐\u003C/span>用药细节决定疗效与安全。细致遵循上文要点，有疑问当场咨询医护，让治疗更安心。\u003C/p>\n  \u003C/div>\n\n  \u003C!-- 11 主要参考文献 -->\n  \u003Cdiv class=\"custom-section\">\n    \u003Cdiv class=\"custom-section-bg\">📚\u003C/div>\n    \u003Ch2 class=\"custom-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">11 主要参考文献\u003C/h2>\n    \u003Cul class=\"custom-reference-list\">\n      \u003Cli>Cortés, J., et al. (2022). Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. \u003Cem>New England Journal of Medicine\u003C/em>, 386(12), 1143-1154. https://doi.org/10.1056/NEJMoa2107953\u003C/li>\n      \u003Cli>Kaufman, P. A., et al. (2014). Eribulin vs. capecitabine in previously treated metastatic breast cancer: Results of two phase 3 studies. \u003Cem>Journal of Clinical Oncology\u003C/em>, 32(32), 3720-3731. https://doi.org/10.1200/JCO.2013.54.0021\u003C/li>\n      \u003Cli>Modi, S., et al. (2020). Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. \u003Cem>New England Journal of Medicine\u003C/em>, 382(7), 610-621. https://doi.org/10.1056/NEJMoa1914510\u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\u003C/div>\n\n\u003Cstyle>\n.custom-drug-guide-wrapper {\n  font-family: \"Helvetica Neue\", Arial, \"PingFang SC\", \"Microsoft YaHei\", sans-serif;\n  background-color: #f8fafc;\n  padding: 36px 8% 40px 8%;\n  color: #2E384D;\n  max-width: 900px;\n  margin: 0 auto;\n  border-radius: 12px;\n  box-shadow: 0 2px 16px rgba(77, 93, 142, 0.06);\n}\n.custom-main-title {\n  text-align: center;\n  font-size: 2.3em;\n  font-weight: bold;\n  color: #0A265F;\n  margin-bottom: 24px;\n  line-height: 1.2;\n  letter-spacing: 1px;\n  padding: 14px 0 8px 0;\n}\n\n.custom-intro-section {\n  font-size: 1.14em;\n  background: linear-gradient(90deg,#f5f7fa 65%,#dbeafe 100%);\n  border-radius: 10px;\n  padding: 16px 24px;\n  margin-bottom: 32px;\n}\n\n.custom-intro-text {\n  color: #505a6a;\n  letter-spacing: 0.2px;\n  display: inline-block;\n  line-height: 1.6;\n}\n\n.custom-section {\n  background: linear-gradient(90deg,#f6fafd 60%,#c8e7fa 100%);\n  border-radius: 10px;\n  margin-bottom: 30px;\n  padding: 28px 24px 24px 28px;\n  box-shadow: 0 1px 7px rgba(186,208,242,0.13);\n  position: relative;\n  min-height: 56px;\n}\n\n.custom-section-bg {\n  position: absolute;\n  font-size: 36px;\n  top: 24px;\n  right: 24px;\n  opacity: 0.23;\n  pointer-events: none;\n  user-select: none;\n}\n.custom-section-title {\n  font-size: 1.34em;\n  font-weight: 600;\n  color: #07477C;\n  margin-bottom: 14px;\n  letter-spacing: .5px;\n  z-index: 5;\n}\n\n.custom-clean-list {\n  margin: 0 0 0 8px;\n  padding: 0;\n  list-style: none;\n  font-size: 1.05em;\n}\n.custom-clean-list li {\n  margin-bottom: 10px;\n  padding-left: 0.4em;\n  line-height: 1.9;\n}\n\n.custom-tip {\n  color: #1976d2;\n  font-weight: 500;\n  padding-left: .1em;\n}\n\n.custom-data-highlight {\n  color: #199166;\n  background: #e5f5e3;\n  border-radius: 3px;\n  padding: 2px 7px;\n  margin-right: 6px;\n  font-size: 1em;\n}\n\n.custom-summary {\n  margin-top: 16px;\n  padding: 10px 28px;\n  background: #e0edfa;\n  border-radius: 7px;\n  font-size: 1.11em;\n  color: #244471;\n}\n.custom-summary-emoji {\n  font-size: 1.4em;\n  margin-right: 6px;\n  vertical-align: middle;\n}\n\n.custom-reference-list {\n  margin: 6px 0 0 0;\n  padding-left: 1em;\n  color: #444c5c;\n  font-size: 1em;\n}\n.custom-reference-list li {\n  margin-bottom: 8px;\n  line-height: 1.7;\n}\n\n@media screen and (max-width: 700px) {\n  .custom-drug-guide-wrapper {\n    padding: 10px 2.5% 10px 2.5%;\n    font-size: 1em;\n  }\n  .custom-section {\n    padding: 20px 11px 18px 15px;\n  }\n  .custom-section-title {\n    font-size: 1.08em;\n  }\n  .custom-main-title {\n    font-size: 1.2em;\n  }\n}\n\u003C/style>\n","\u003Cdiv class=\"custom-drug-guide-wrapper\">\n  \u003Ch2 id=\"material_title\" class=\"custom-main-title\" style=\"c",548,"2025-07-18 18:17:18","乳腺癌, 肺转移, 用药安全, 靶向药物, 不良反应","掌握乳腺癌肺转移的用药安全要点。这篇指南总结了靶向药物、化疗药物的使用规则和不良反应检测方法，帮助患者安全用药，优化治疗效果。","2025-07-19 08:10:00",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]